Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5832109 | 0.95 | CHRNA7 (0.52) | CHRNA7ACACBHTR1AALDH1A1KDM4E | |
| Fumaric Acid SCHEMBL27601359 | 0.90 | CHRNA7 (0.46) | CHRNA7ACACBHTR1AKCNH2CHKA | |
| SCHEMBL5832247 | 0.84 | HTR3A (0.59) | — | |
| SCHEMBL5465191 | 0.81 | HTR3A (0.54) | HRH3 | |
| SCHEMBL4208987 | 0.79 | CHRNA7 (0.52) | CHRNA7ACACBHTR1AALDH1A1KDM4E | |
| SCHEMBL5832796 | 0.76 | HTR3A (0.51) | HRH3 | |
| SCHEMBL4216672 | 0.76 | CHRNA7 (0.54) | CHRNA7ACACBHTR1AALDH1A1KDM4E | |
| SCHEMBL4212685 | 0.76 | GAA (0.67) | CHRNA7HTR1AALDH1A1KDM4EGAA | |
| SCHEMBL30604112 | 0.75 | CHRNA7 (0.48) | CHRNA7ACACBHTR1AALDH1A1KDM4E | |
| SCHEMBL2253917 | 0.74 | KHK (0.47) | CHRNA7ACACBALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060699-B2 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2006-06-13 | — | — | US | claimed |
| EP-1301514-B1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2005-01-26 | — | — | EP | claimed |
| CN-1185233-C | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2005-01-19 | — | — | CN | claimed |
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | claimed |
| CN-1440411-A | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | CN | claimed |
| US-20100267739-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | OLSEN GUNNAR M | 2010-10-21 | — | — | US | disclosed |
| CN-100398103-C | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH AS (DK) | 2008-07-02 | — | — | CN | disclosed |
| US-7307087-B2 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH A/S (DK) | 2007-12-11 | — | — | US | disclosed |
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | OLSEN GUNNAR M | 2007-11-15 | — | — | US | disclosed |
| EP-1757600-A2 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NeuroSearch A/S (DK) | 2007-02-28 | — | — | EP | disclosed |
| US-7060699-B2 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2006-06-13 | — | — | US | disclosed |
| CN-1635877-A | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH AS (DK) | 2005-07-06 | — | — | CN | disclosed |
| CN-1185233-C | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2005-01-19 | — | — | CN | disclosed |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | ANIONA APS (DK) | 2004-05-13 | — | — | US | disclosed |
| EP-1358177-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NeuroSearch A/S (DK) | 2003-11-05 | — | — | EP | disclosed |
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| CN-1440411-A | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | CN | disclosed |
| EP-1301514-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002030405-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002002564-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885ACACB 1014/4885HTR1A 77/4885 |
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | TAAR5, CHRNA5, CHRNA4 | CHRNA7 7/4885ACACB 2221/4885HTR1A 17/4885 |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | TAAR5, CHRNA5, CHRNA4 | CHRNA7 7/4885ACACB 2221/4885HTR1A 17/4885 |
| US-20100267739-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | CHRNA10, CHRNA2, CHRNA7 | CHRNA7 3/4885ACACB 2296/4885HTR1A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.